Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties

Archive ouverte

Beaudart, Charlotte | Reginster, Jean-Yves | Amuthavalli Thiyagarajan, Jotheeswaran | Bautmans, Ivan | Bauer, Jürgen | Burlet, Nansa | Cesari, Matteo | Cherubini, Antonio | Cooper, Cyrus | Cruz-Jentoft, Alfonso, J | Dawson-Hughes, Bess | Fielding, Roger, A | Harvey, Nicholas, C | Landi, Francesco | Laslop, Andrea | Maggi, Stefania | Montero-Errasquin, Beatriz | Concepción, Prieto Yerro María | Rolland, Yves | Rizzoli, René | Visser, Marjolein | Bruyère, Olivier

Edité par CCSD ; Springer Verlag -

International audience. Patient perspectives are now widely recognized as a key element in the evaluation of health interventions. Therefore, the provision of specific and validated Patient Reported Outcome Measures that emphasize the lived experience of patients suffering from specific diseases is very important. In the field of sarcopenia, the only validated specific health-related quality of life (HRQoL) instrument available is the Sarcopenia Quality of Life questionnaire (SarQoL). This self-administrated HRQoL questionnaire, developed in 2015, consists of 55 items arranged into 22 questions and has currently been translated into 35 languages. Nineteen validation studies performed on SarQoL have consensually confirmed the capacity of SarQoL to detect difference in HRQoL between older people with and without sarcopenia, its reliability and its validity. Two further observational studies have also indicated its responsiveness to change. A short form SarQoL, including only 14 items has further been developed and validated to reduce the potential burden of administration. Research on the psychometric properties of SarQoL questionnaire is still encouraged as the responsiveness to change of SarQoL has not yet been measured in the context of interventional studies, as limited prospective data currently exist and as there is still not cut-off score to define a low HRQoL. In addition, SarQoL has mainly been used in community-dwelling older individuals with sarcopenia and would benefit to be studied in other types of populations. This review aims to provide to researchers, clinicians, regulators, pharmaceutical industries and other stakeholders a clear summary of comprehensive evidence on the SarQoL questionnaire published up to January 2023Query.

Suggestions

Du même auteur

Assessment of Muscle Function and Physical Performance in Daily Clinical Practice

Archive ouverte | Beaudart, Charlotte | CCSD

International audience. It is well recognized that poor muscle function and poor physical performance are strong predictors of clinically relevant adverse events in older people. Given the large number of approaches...

Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults

Archive ouverte | Reginster, Jean-Yves | CCSD

International audience. Background In 2016, an expert working group was convened under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and formulated...

Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review

Archive ouverte | Bauer, Jürgen | CCSD

International audience. The co-existence of impaired bone health (osteopenia/osteoporosis), reduced muscle mass and strength (sarcopenia), and increased adiposity (obesity) in middle-aged and older people has been i...

Chargement des enrichissements...